Agreement will leverage Evinova’s innovative AI-native platform to improve trial design, accelerate timelines, and enhance cost efficiency
Evinova has announced a new collaboration with Bristol Myers Squibb focused on improving the way clinical trials are designed and executed using artificial intelligence. As part of the agreement, Bristol Myers Squibb will implement the Cost Optimizer module within Evinova’s Study Designer across its global development portfolio. The goal is to apply AI-driven insights to trial planning, helping teams make better decisions earlier, uncover operational efficiencies, and design studies that move faster while improving the experience for research sites and participants.
Health Technology Insights: Hikma Launches EXOMIND, FDA-Cleared Drug-Free Depression Therapy
Through this partnership, Bristol Myers Squibb will leverage Evinova’s AI-native clinical development platform to analyze complex trial variables, highlight productivity opportunities, and support more efficient and patient-friendly trial designs. By embedding advanced analytics into study planning, both organizations aim to reduce unnecessary complexity, shorten timelines, and enable smarter allocation of resources across programs.
Health Technology Insights: Rx Assistant Launches AI Hub for Medication Access and Adherence
Cristina Duran, President of Evinova, said the pace of change in drug development requires life sciences companies to work with partners that understand both technology and clinical research. She explained that Evinova was built by pharmaceutical experts to address real-world development challenges and combines advanced AI capabilities with deep industry knowledge. According to Duran, the collaboration with Bristol Myers Squibb reflects a shared commitment to improving efficiency in clinical development and delivering meaningful progress for patients sooner.
Cristian Massacesi, MD, Executive Vice President, Chief Medical Officer and Head of Development at Bristol Myers Squibb, emphasized that modernizing clinical development has become a critical priority. He noted that traditional approaches have often been slow, costly, and prone to failure, and that digital tools and AI offer a way to overcome these long-standing barriers. Massacesi highlighted that decisions made today around technology adoption will influence how quickly new medicines reach patients and how effectively scientific advances translate into better health outcomes.
Evinova’s AI-native platform is designed to support end-to-end clinical development by enhancing study design, enabling collaboration, and facilitating consistent digital data flow using USDM standards. The platform includes built-in governance measures to support responsible AI use and has already delivered significant cost savings and operational improvements for customers at global scale.
In addition, Evinova’s Unified Trial Solution connects key trial components into a single, streamlined experience for sponsors, sites, and patients. The solution integrates electronic clinical outcome assessments with telehealth capabilities and connected devices for remote patient monitoring, supporting improved data collection, toxicity management, and innovative trial designs. Developed with direct input from patients and site teams, the platform emphasizes usability and engagement, contributing to high compliance and strong user satisfaction.
Together, Evinova and Bristol Myers Squibb aim to set a new standard for AI-enabled clinical development that accelerates timelines, improves data quality, reduces burden on participants, and ultimately supports better outcomes for patients worldwide.
Health Technology Insights: Health Technology Insights: Latest News And Innovations – Roundup 4 February 2026
To participate in our interviews, please write to our HealthTech Media Room at info@intentamplify.com
